GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
GT Biopharma, Inc. (GTBP), a Delaware corporation, filed this Current Report on Form 8-K on September 15, 2026, regarding events occurring on September 14, 2026. The Company operates as a fully remote entity with no principal executive office, directing communications to San Francisco, California.
Key Financial Metrics and Transaction Details
This filing details a private placement financing event rather than periodic financial performance metrics. Key transaction figures include:
- Aggregate Purchase Price: $7,450,000 for the initial offering.
- Securities Issued: Up to 8,277.778 shares of Series M 10% Convertible Preferred Stock with an aggregate stated value of $8,277,778.
- Warrants: Issuance of Common Warrants (100% of conversion shares) and Vesting Warrants (linked to Greenshoe exercise).
- Greenshoe Option: Purchasers may elect to purchase additional Preferred Stock with an aggregate stated value of up to $33,333,333 for a purchase price of $30,000,000.
- Conversion Price: Initial conversion price of $6.10 per share.
- Dividends: Cumulative dividends at 10% per annum until September 13, 2027, increasing to 12% per annum thereafter.
The filing does not provide revenue, profit, cash flow, or debt metrics for the reporting period.
Material Changes and Agreements
The Company entered into several material definitive agreements:
- Securities Purchase Agreement: Governs the issuance of Preferred Stock and Warrants with full ratchet price protection.
- Registration Rights Agreement: Requires the Company to file a registration statement within 30 days of closing. Failure to meet deadlines incurs liquidated damages of 1.5% of the subscription amount, plus interest at the prime rate plus 12% if unpaid within seven days.
- Voting Agreement: Officers and directors agreed to vote in favor of shareholder approval for the issuance of more than 19.99% of outstanding common stock.
- Lock-Up Agreement: Officers and directors are restricted from selling securities for 30 days after the later of the registration statement effective date or shareholder approval.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the financing. Key risks and contingencies include:
- Shareholder Approval: The transaction requires shareholder approval to issue more than 19.99% of outstanding common stock.
- Dilution: The issuance includes full ratchet anti-dilution protection, which may significantly impact existing shareholders if future issuances occur at lower prices.
- Financial Obligations: The Company faces potential liquidated damages and high-interest penalties if registration filing deadlines are missed.
- Dividend Liability: The Company assumes a cumulative dividend obligation of 10% to 12% annually on the Preferred Stock.
Investor Verification Checklist
- Verify the outcome of the required shareholder vote for the issuance of >19.99% of common stock.
- Confirm the total number of shares issued upon exercise of the $30,000,000 Greenshoe option.
- Monitor the Company's ability to file the registration statement within the 30-day deadline to avoid liquidated damages.
- Assess the impact of the 10-12% cumulative dividend requirement on the Company's cash flow.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific conditions on dividend payment (cash vs. stock) and conversion triggers.